BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2026.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115387
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115387
Figure 1
Figure 1 Evaluation the variation of geriatric nutritional risk index and pan-immune-inflammation value during neoadjuvant chemotherapy. A and B: The changes in geriatric nutritional risk index (GNRI) and pan-immune-inflammation value (PIV) during neoadjuvant chemotherapy; C and D: The influence of nutritional intervention on GNRI and PIV; E and F: The influence of no nutritional supplementation on GNRI and PIV.
Figure 2
Figure 2 Survival analysis in different group. A and B: Kaplan-Meier plot lines of overall survival for different geriatric nutritional risk index (GNRI) and pan-immune-inflammation value (PIV) groups; C and D: Disease-free survival for different GNRI and PIV groups; E and F: Overall survival and disease-free survival for different GNRI-PIV score groups. OS: Overall survival; GNRI: Geriatric nutritional risk index; PIV: Pan-immune-inflammation value; DFS: Disease-free survival.
Figure 3
Figure 3 Postoperative pathologic response between different geriatric nutritional risk index-pan-immune-inflammation value score groups. A: Distribution of College of American Pathologists (CAP) grading in patients with a geriatric nutritional risk index (GNRI)-pan-immune-inflammation value (PIV) score of 0; B: CAP grading in patients with a GNRI-PIV score of 1; C: CAP grading in patients with a GNRI-PIV score of 2. GNRI: Geriatric nutritional risk index; PIV: Pan-immune-inflammation value; CAP: College of American Pathologists.